MELISSA SUMMERLIN: Open Payments
NPI 1043519671 · GAINESVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,660 in 72 payments from 27 companies in 2025. Trend: 2023 $2,136 · 2024 $1,516 · 2025 $1,660
Food & beverage: $1,660
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $185 |
| Celgene Corporation | 8 | $178 |
| PFIZER INC. | 4 | $98 |
| Exelixis Inc. | 4 | $95 |
| Novartis Pharmaceuticals Corporation | 4 | $91 |
| AstraZeneca Pharmaceuticals LP | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $86 |
| Merck Sharp & Dohme LLC | 3 | $76 |
| GlaxoSmithKline, LLC. | 3 | $75 |
| Janssen Biotech, Inc. | 3 | $70 |
Products named: REBLOZYL, EPKINLY, CABOMETYX, VENCLEXTA, KEYTRUDA, Nubeqa, KISQALI, FRUZAQLA.
Industry payments across GA — which companies pay providers there.
